ARE Stock Analysis: Alexandria Real Estate | NYSE
REIT - Office | NYSE, USA | Market Cap: 7.032m USD | 12M Return: -9.7% | US0152711091 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 110M
Qual. Beats: 0
Rev. Trend: 0.9%
Qual. Beats: 0
Warnings
Tailwinds
No distinct edge detected
Seasonality 11.7 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Alexandria Real Estate Equities (NYSE: ARE) is an S&P 500 life science REIT founded in 1994 and widely credited with pioneering the life science real estate niche. The company owns, operates, and develops collaborative Megacampus ecosystems in top-tier innovation cluster locations, including Greater Boston, San Diego, the San Francisco Bay Area, Seattle, Maryland, Research Triangle, and New York City. The company is incorporated in Maryland and trades as a mid-cap stock following its 1997 IPO, and is the longest-tenured operator in its niche.
As a specialized REIT, Alexandria leases laboratory and research facilities to tenants in the pharmaceutical, biotechnology, and medical technology sectors. Under U.S. tax rules, REITs must distribute at least 90% of their taxable income to shareholders as dividends, which typically positions REIT shares as income-oriented holdings relative to the broader equity market.
- Biotech venture funding rebound lifts lab occupancy
- Interest rate cuts ease REIT cap rate pressure
- Megacampus development pipeline expands in Boston and San Diego
| Net Income: -1.31b TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.01 > 0.02 and ΔFCF/TA -2.49 > 1.0 |
| NWC/Revenue: -89.95% < 20% (prev -84.98%; Δ -4.97% < -1%) |
| CFO/TA 0.03 > 3% & CFO 1.19b > Net Income -1.31b |
| Current Ratio: 0.18 > 1.5 & < 3 |
| Outstanding Shares: last quarter (170.8m) vs 12m ago 0.36% < -2% |
| Gross Margin: 69.16% > 18% (prev 68.77%; Δ 0.39% > 0.5%) |
| Asset Turnover: 8.10% > 50% (prev 7.97%; Δ 0.13% > 0%) |
| Interest Coverage Ratio: -4.46 > 6 (EBIT TTM -1.22b / Interest Expense TTM 274.3m) |
| DSRI: 0.10 (Receivables 6.17m/284.8m, Revenue 2.89b/2.98b) |
| GMI: 0.99 (GM 68.77% / 69.16%) |
| AQI: 0.13 (AQ_t 0.12 / AQ_t-1 0.94) |
| SGI: 0.97 (Revenue 2.89b / 2.98b) |
| TATA: -0.07 (NI -1.31b - CFO 1.19b) / TA 34.1b) |
| Beneish M = -4.32 (Cap -4..+1) = AAA |
As of November 05, 2026, the stock is trading at USD 46.00 with a total of 4,701,322 shares traded. Over the past week, the price has changed by +15.26%, over one month by +0.26%, over three months by -4.45% and over the past year by -9.68%.
Current recommended Stop Loss: 43.60 (which is 5.2% or 1.3 ATR below the current price).
Alexandria Real Estate has received a consensus analysts rating of 2.88. Therefore, it is recommended to hold ARE.
- StrongBuy: 2
- Buy: 0
- Hold: 10
- Sell: 2
- StrongSell: 2
| Analysts Target Price | 51 | 10.9% |
P/E Forward = 16.6945
P/S = 2.4757
P/B = 0.4802
P/EG = 3.2356
Revenue TTM = 2.89b USD
EBIT TTM = -1.22b USD
EBITDA TTM = 13.6m USD
Long Term Debt = 11.8b USD (from longTermDebt, last quarter)
Short Term Debt = 1.09b USD (from shortTermDebt, last quarter)
Debt = 13.6b USD (from shortLongTermDebtTotal, last quarter) + Leases 354.0m
Net Debt = 13.1b USD (calculated: Debt 13.6b - CCE 508.9m)
Enterprise Value = 20.1b USD (7.03b + Debt 13.6b - CCE 508.9m)
Interest Coverage Ratio = -4.46 (Ebit TTM -1.22b / Interest Expense TTM 274.3m)
EV/FCF = 49.61x (Enterprise Value 20.1b / FCF TTM 405.7m)
FCF Yield = 2.02% (FCF TTM 405.7m / Enterprise Value 20.1b)
FCF Margin = 14.03% (FCF TTM 405.7m / Revenue TTM 2.89b)
Net Margin = -45.25% (Net Income TTM -1.31b / Revenue TTM 2.89b)
Gross Margin = 69.16% ((Revenue TTM 2.89b - Cost of Revenue TTM 892.0m) / Revenue TTM)
Gross Margin QoQ = 66.04% (prev 73.95%)
Tobins Q-Ratio = 0.59 (Enterprise Value 20.1b / Total Assets 34.1b)
Interest Expense / Debt = 2.02% (Interest Expense 274.3m / Debt 13.6b)
Taxrate = 21.0% (US federal default 21%)
NOPAT = -966.0m (EBIT -1.22b * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 0.18 (Total Current Assets 564.8m / Total Current Liabilities 3.17b)
Debt / Equity = 0.92 (Debt 13.6b / totalStockholderEquity, last quarter 14.8b)
Debt / EBITDA = 966.4 (Net Debt 13.1b / EBITDA 13.6m)
Debt / FCF = 32.28 (Net Debt 13.1b / FCF TTM 405.7m)
Total Stockholder Equity = 15.4b (last 4 quarters mean from totalStockholderEquity)
RoA = -3.67% (Net Income -1.31b / Total Assets 34.1b)
RoE = -8.50% (Net Income TTM -1.31b / Total Stockholder Equity 15.4b)
RoCE = -4.50% (EBIT -1.22b / Capital Employed (Equity 15.4b + L.T.Debt 11.8b))
RoIC = -3.03% (negative operating profit) (NOPAT -966.0m / Invested Capital 31.8b)
WACC = 3.28% (E(7.03b)/V(20.6b) * Re(6.55%) + D(13.6b)/V(20.6b) * Rd(2.02%) * (1-Tc(0.21)))
Discount Rate = 6.55% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 45.87 | Cagr: -0.33%
[DCF] Terminal Value 73.10% ; FCFF base≈793.8m ; Y1≈696.1m ; Y5≈562.4m
[DCF] Fair Price = N/A (negative equity: EV 9.03b - Net Debt 13.1b = -4.07b; debt exceeds intrinsic value)
EPS Correlation: N/A | EPS CAGR: N/A | SUE: 0.01 | # QB: 0
Revenue Correlation: 0.88 | Revenue CAGR: 0.02% | SUE: 0.21 | # QB: 0
EPS current Quarter (2027-03-31): EPS=-0.14 | Chg30d=+0.00% | Revisions=-40% | Analysts=4
EPS current Year (2026-12-31): EPS=1.40 | Chg30d=-3.89% | Revisions=-25% | GrowthEPS=+116.6% | GrowthRev=-12.2%
EPS next Year (2027-12-31): EPS=-0.81 | Chg30d=+7.95% | Revisions=+25% | GrowthEPS=-134.7% | GrowthRev=-4.6%
[Analyst] Revisions Ratio: -29% (up=1, down=3)